US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
pharma · Not applicable, healthy volunteers · ulcerative pyoderma gangrenosum
InflaRx
InflaRx GmbH
InflaRx drug portfolio — 20 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Jena, DE HQ
2007 Founded
52 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Jena, DE
- Founded
- 2007
- Employees
- 52
- Programs
- 4
- Drugs
- 20
- Patents
- 0
InflaRx pipeline
Portfolio lens on 20 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
InflaRx drug portfolio — 20 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to InflaRx in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to InflaRx in public FDA and regional records.
-
Development asset linked to InflaRx in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to InflaRx in public FDA and regional records.
-
Development asset linked to InflaRx in public FDA and regional records.
-
Development asset linked to InflaRx in public FDA and regional records.
-
hydrocortisone
Systemic hormonal preparations (H02)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to InflaRx in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
vilobelimab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in InflaRx's portfolio. Molecular target: Complement C5.
- Target
- Complement C5
- Mechanism
- Complement C5 inhibitor